VELIPARIB WITH FIRST-LINE CHEMOTHERAPY AND AS MAINTENANCE THERAPY IN OVARIAN CANCER
The poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor veliparib plus platinum-based chemotherapy for induction therapy, followed by maintenance therapy with veliparib, improves progression-free survival (PFS) in the initial treatment of high-grade serous ovarian carcinoma, according to a study published online Sept. 28 in the New England Journal of Medicine. The researchers found that among women with a BRCA mutation, […]
VELIPARIB WITH FIRST-LINE CHEMOTHERAPY AND AS MAINTENANCE THERAPY IN OVARIAN CANCER Read More »
